Protecting Hearts During Cancer Treatment: A New Hope with Remote Ischemic Conditioning
Advances in cancer treatment are leading to higher survival rates, but the powerful drugs used to fight cancer can sometimes leave a lasting impact on the heart. Anthracyclines, a class of chemotherapy drugs, are known to cause cardiac damage, affecting patients’ quality of life long after treatment ends. Now, research offers a promising, non-invasive approach to mitigate this risk.
The Challenge of Cardio-Oncology
Protecting the heart while maintaining the effectiveness of chemotherapy is a central challenge in cardio-oncology. Traditional approaches often involve careful monitoring and, in some cases, adjusting chemotherapy dosages, which can potentially compromise treatment efficacy. Researchers are actively seeking ways to shield the heart without diminishing the fight against cancer.
Remote Ischemic Conditioning: A Simple Solution?
A recent study demonstrates that a technique called remote ischemic conditioning (RIC) may offer a solution. RIC involves briefly restricting blood flow to a limb – typically using a blood pressure cuff – to activate the body’s natural protective mechanisms. This process prepares the heart to better withstand stressors, like the damage caused by anthracyclines.
Researchers at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) conducted a study using mice treated with anthracyclines. The results showed that animals receiving RIC maintained better cardiac function during treatment. Crucially, this cardioprotective effect did not hinder the chemotherapy’s ability to fight tumors.
“Showing that the heart can be protected without compromising cancer treatment is essential to developing safer therapies,” explains Anabel Díaz Guerra, a CNIC predoctoral researcher.
Clinical Trials on the Horizon
The CNIC team is currently coordinating the European clinical trial RESILIENCE, which aims to evaluate whether RIC can protect the hearts of cancer patients undergoing anthracycline treatment and reduce long-term cardiovascular complications. This trial builds on the promising findings from the experimental model.
How Does RIC Operate?
RIC triggers a systemic response that enhances the heart’s resilience. The brief periods of ischemia (restricted blood flow) stimulate the release of protective factors that reduce oxidative stress and inflammation – key contributors to anthracycline-induced cardiotoxicity. While the exact mechanisms are still being investigated, the results suggest a powerful, naturally-occurring defense system can be harnessed.
Beyond Anthracyclines: A Broader Impact?
While this research focuses on anthracycline cardiotoxicity, the principles of RIC may extend to other cancer treatments with cardiovascular side effects. HER2-targeted therapies and fluoropyrimidines are also known to impact heart health, and future studies could explore the potential benefits of RIC in these contexts.
Strict control of cardiovascular risk factors remains pivotal during cancer treatments to prevent or reduce toxic effects on the cardiovascular system. A tailored clinical and instrumental surveillance, including echocardiograms and cardiac biomarkers, is recommended for early detection of cardiovascular toxicity.
Did you know?
Cancer therapy-related cardiac dysfunction (CTRCD) is defined by decreases in left ventricular ejection fraction (LVEF) greater than 10% to less than 50% or a greater than 15% relative decrease in global longitudinal strain (GLS) from baseline.
Frequently Asked Questions
What are anthracyclines?
Anthracyclines are powerful chemotherapy drugs used to treat a variety of cancers, including lymphomas, acute leukemias, and soft tissue sarcomas.
What is remote ischemic conditioning?
RIC is a non-invasive technique involving brief interruptions of blood flow to a limb, which activates protective mechanisms in the body.
Is RIC widely available?
RIC is currently being investigated in clinical trials. This proves not yet a standard part of cancer treatment protocols, but research is ongoing.
What are the long-term effects of anthracycline cardiotoxicity?
Long-term effects can include heart failure, reduced exercise capacity, and a decreased quality of life.
Pro Tip
Maintaining a healthy lifestyle, including regular exercise and a balanced diet, can help mitigate cardiovascular risk factors during and after cancer treatment.
This research represents a significant step forward in cardio-oncology, offering a potentially simple and effective way to protect the hearts of cancer patients. As clinical trials progress, we may see RIC become a standard component of cancer care, improving outcomes and enhancing the quality of life for survivors.
Learn more about cancer treatment and heart health: American College of Cardiology